There are more than 1,000 different kinds of blood disorders, which affect how blood cells are produced, function or clot. Many are chronic and complex, requiring specialized care and access to high-cost medications.  

Hemophilia, a rare condition that impacts more than 1 million people globally, is one of the most expensive blood disorders to treat — from $250,000 to more than $1 million per patient, according to the National Bleeding Disorders Foundation. Prime Therapeutics (Prime) helps manage drug costs and simplify the patient experience through its industry-leading solutions — integrated offerings grounded in clinical expertise, advanced analytics and a holistic view of member health.  

A holistic approach to hemophilia management 

Prime’s comprehensive hemophilia solution brings together multiple capabilities to address the full spectrum of care. This includes:  

• Personalization of therapy that helps make sure patients receive the right treatment at the right dosage  
• Increased transparency and data collection to inform clinical decision-making and identify opportunities for optimization 
• Pharmacy inventory and assay management to reduce waste, improve product handling and support continuity of care 

By integrating these elements, Prime helps ensure members receive clinically appropriate treatment while plans gain greater visibility into utilization and cost drivers. 

Prime’s comprehensive hemophilia management solution has generated more than $40 million in savings since 2017, according to an internal analysis.  

HighTouchRx^®: supporting specialty medication management 

Prime’s HighTouchRx solution also supports Prime’s holistic hemophilia strategy by delivering specialized pharmacy services for complex, high-cost therapies like blood disorders. Through targeted prescriber outreach, HighTouchRx helps ensure use of appropriately optimized drug therapy, helping clients contain associated treatment costs.  

Since April 2022, HighTouchRx has saved commercial and Medicare plans more than $150 million, including costs for hemophilia medications. 

“This high-touch model is especially important for hemophilia, where missed doses, incorrect administration or supply issues can have serious clinical and financial consequences,” said Marie Wimmer, Prime’s director of program capabilities.   

Best in Care: aligning treatment with evidence and outcomes 

For clients looking to protect their return on investment made in drug therapy, Best in Care offers flexible value-based contracts — providing discounts, cost caps and clinical management to support better health outcomes. The extra layer of management in both traditional and specialty drug categories helps health plans be more competitive in the commercial space. 

“Best in Care helps ensure drug spending translates into better outcomes,” said Michelle Jacobson, senior client relations director. “That extra layer of support across traditional and specialty therapies gives health plans greater confidence, and a stronger competitive edge, in the commercial space.”  

---

Learn more about how Prime manages hemophilia